Related Experiment Videos
Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery
Cancer
|June 1, 1979
Summary
Preoperative chemotherapy, including high-dose methotrexate (HDMTX) with citrovorum factor rescue (CFR), significantly improved survival rates for osteogenic sarcoma patients. Escalating HDMTX doses enhanced treatment effectiveness, leading to disease-free survival in most patients.
Area of Science:
- Oncology
- Surgical Oncology
- Medical Oncology
Background:
- Osteogenic sarcoma is a primary bone cancer requiring aggressive treatment.
- Traditional treatment often involves amputation, impacting patient quality of life.
- The need for limb-sparing surgical techniques and effective systemic therapies is critical.
Purpose of the Study:
- To evaluate the efficacy of preoperative chemotherapy in treating primary osteogenic sarcoma.
- To assess the impact of high-dose methotrexate (HDMTX) with citrovorum factor rescue (CFR) on tumor response.
- To determine if preoperative chemotherapy can facilitate limb-sparing surgery and improve patient outcomes.
Main Methods:
- A cohort of 31 patients with osteogenic sarcoma received 3 months of preoperative chemotherapy (HDMTX, adriamycin, CFR) followed by surgery.
- Surgery was delayed to allow for custom prosthetic implants, aiming to avoid amputation.
- Postoperative chemotherapy included cyclophosphamide for approximately 5 months.
- A subsequent group of 20 patients received a more aggressive preoperative regimen (T-7) with dose escalation of HDMTX.
Main Results:
- At 30-52 months follow-up, 75% (23/31) of patients survived, with 21 disease-free.
- Histologic examination showed significant tumor destruction from chemotherapy, correlating with better survival.
- Dose escalation of HDMTX was necessary in some cases to achieve optimal tumor response.
- In the T-7 group, 19/20 patients showed good clinical response, with most having no viable tumor post-surgery and all surviving disease-free at brief follow-up.
Conclusions:
- Preoperative chemotherapy, particularly with dose-escalated HDMTX, is an effective strategy for osteogenic sarcoma.
- This approach allows for evaluation of chemotherapy effectiveness, eradication of micrometastases, and facilitates limb-sparing surgery.
- The findings support the routine use of preoperative chemotherapy in osteogenic sarcoma management to improve survival and limb salvage rates.